Page last updated: 2024-08-23

tobramycin and Age-Related Macular Degeneration

tobramycin has been researched along with Age-Related Macular Degeneration in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brown, GC; Garg, SJ; Haller, JA; Kaiser, RS; Shah, CP; Vander, JF	1

Other Studies

1 other study(ies) available for tobramycin and Age-Related Macular Degeneration

Article	Year
Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology, 2011, Volume: 118, Issue:10 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aqueous Humor; Bevacizumab; Case-Control Studies; Ceftazidime; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Ranibizumab; Retrospective Studies; Risk Factors; Tobramycin; Treatment Outcome; Vancomycin; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body	2011

Article

Year

Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.

Ophthalmology, 2011, Volume: 118, Issue:10

Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aqueous Humor; Bevacizumab; Case-Control Studies; Ceftazidime; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Ranibizumab; Retrospective Studies; Risk Factors; Tobramycin; Treatment Outcome; Vancomycin; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body

2011